Earnings ·
OptimizeRx Corporation reported second quarter 2026 financial results with revenue of $20.5 million, a 30% decrease…
OPRXOptimizeRx Corp
OptimizeRx Corporation reported second quarter 2026 financial results with revenue of $20.5 million, a 30% decrease from the prior year period, and a GAAP net loss of $(0.7) million. The company reaffirmed its full-year 2026 guidance for revenue between $95 million and $100 million and adjusted EBITDA between $21 million and $25 million. Concurrently, the Board approved a finance leadership succession plan effective January 1, 2027. Edward Stelmakh will step down as Chief Financial & Strategy Officer on December 31, 2026, receiving severance including 12 months of salary continuation totaling $450,000 and a one-time bonus payment of $247,500. Andrew D’Silva is appointed as the new Chief Financial Officer with an annual base salary of $375,000, and Heather Favazza is appointed as Chief Accounting Officer with an annual base salary of $325,000. OptimizeRx operates in the healthcare technology industry, providing AI-driven audience intelligence and programmatic engagement solutions for life sciences companies to connect with healthcare professionals and patients.